2019
PLEKHA5 regulates tumor growth in metastatic melanoma
Zhang H, Zhu H, Deng G, Zito CR, Oria VO, Rane CK, Zhang S, Weiss SA, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg MW, Kluger HM, Jilaveanu LB. PLEKHA5 regulates tumor growth in metastatic melanoma. Cancer 2019, 126: 1016-1030. PMID: 31769872, PMCID: PMC7147081, DOI: 10.1002/cncr.32611.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnimalsApoptosis Regulatory ProteinsBiomarkers, TumorBrain NeoplasmsCell ProliferationFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsMaleMelanomaMiceMice, NudeMiddle AgedPhosphatidylinositol 3-KinasesPrognosisProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesTumor Cells, CulturedXenograft Model Antitumor AssaysYoung AdultConceptsTumor growthDisseminated melanomaExtracranial melanoma metastasesPI3K/AKT/mTOR pathwayMelanoma brain metastasesBetter overall survivalPI3K/Akt/mTORAKT/mTOR pathwayCell proliferationAkt/mTORMelanoma xenograft modelGrowth of tumorsS cell cycle transitionBrain metastasesOverall survivalPoor prognosisMetastatic melanomaMAPK/ERKSubcutaneous inoculationMelanoma metastasesXenograft modelClinical relevanceMelanoma growthNude miceCerebral specimens
2016
Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts
Weiss SA, Han J, Darvishian F, Tchack J, Han SW, Malecek K, Krogsgaard M, Osman I, Zhong J. Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. Journal Of Translational Medicine 2016, 14: 299. PMID: 27760559, PMCID: PMC5070187, DOI: 10.1186/s12967-016-1026-2.Peer-Reviewed Original ResearchMeSH KeywordsAgedAgingCohort StudiesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunityLymphocytes, Tumor-InfiltratingMaleMelanomaMiddle AgedMultivariate AnalysisNeoplasm StagingPrognosisSEER ProgramSurvival AnalysisConceptsMelanoma-specific survivalShorter melanoma-specific survivalHost immune responseImmune responseTCGA cohortAge groupsClinicopathologic featuresSurvival outcomesPatient cohortPrimary melanomaHost anti-tumor immune responseMelanoma diagnosisAnti-tumor immune responseMelanoma Cooperative GroupIndependent prognostic factorPopulation-based surveillanceEnd Results ProgramGreater prognostic impactMelanoma patient cohortTop upstream regulatorsYounger age groupsAge-related factorsBrisk TILsConclusionsOlder ageLymphocyte measurementsImmunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma
Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. Human Pathology 2016, 57: 116-125. PMID: 27473267, PMCID: PMC5706446, DOI: 10.1016/j.humpath.2016.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorCD3 ComplexDisease-Free SurvivalFemaleForkhead Transcription FactorsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateLeukocyte Common AntigensLymphocytes, Tumor-InfiltratingMaleMelanomaNeoplasm GradingPhenotypeProportional Hazards ModelsSkin NeoplasmsTime FactorsTreatment OutcomeConceptsAbsent tumor-infiltrating lymphocytesTumor-infiltrating lymphocytesBrisk tumor-infiltrating lymphocytesRecurrence-free survivalPrimary melanomaTIL gradeOverall survivalImmunologic heterogeneityPresence of TILsHost antitumor immune responseAntitumor immune responseImmune checkpoint regulatorsLymphocyte markers CD3T cell activation pathwaysEosin-stained sectionsGene expression profilesIndependent prognosticationLymphocyte compositionTIL countSurvival outcomesImproved prognosisPrognostic valueHistologic evaluationNonbriskImmune response